Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy

Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers. Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effe...

Full description

Bibliographic Details
Main Authors: Hao Chen, Zongtao Lin, Kinsie E. Arnst, Duane D. Miller, Wei Li
Format: Article
Language:English
Published: MDPI AG 2017-08-01
Series:Molecules
Subjects:
antibody-drug conjugates
cytotoxic payloads
linker
monoclonal antibody
site-specific conjugation
tubulin inhibitors
Online Access:https://www.mdpi.com/1420-3049/22/8/1281

Internet

https://www.mdpi.com/1420-3049/22/8/1281

Similar Items